TY  - JOUR
T1  - Β-blocker use for patients with or at risk for coronary artery disease
AU  - Shang C
Y1  - 2013/02/06
N1  - 10.1001/jama.2012.128869
JO  - JAMA
SP  - 438
EP  - 438
VL  - 309
IS  - 5
N2  - 
To the Editor: It is unfortunate that the observational study on β-blocker use and clinical outcomes in stable outpatients did not distinguish different types of β-blockers.1 In a review of β-blockers for hypertension, three-quarters of participants in randomized controlled trials (RCTs) used atenolol.2 Atenolol has been shown repeatedly to be no better than placebo in improving clinical outcomes such as reduction of mortality and cardiovascular events in RCTs and meta-analyses.2- 3

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.128869
UR  - http://dx.doi.org/10.1001/jama.2012.128869
ER  -